Article Text

Download PDFPDF
Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In patients with high risk atherothrombosis, is long term treatment with clopidogrel plus aspirin more effective than aspirin alone for reducing cardiovascular (CV) events?

Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★★★☆ Internal medicine ★★★★★★☆ Neurology ★★★★★★☆ Cardiology ★★★★★★☆


Embedded ImageDesign:

randomised placebo controlled trial (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilisation, Management, and Avoidance [CHARISMA]).

Embedded ImageAllocation:


Embedded ImageBlinding:

blinded {clinicians, patients, data collectors, outcome assessors, data analysts, and data safety and monitoring committee}.*

Embedded ImageFollow up period:

median 28 months.

Embedded ImageSetting:

768 sites in 32 countries.

Embedded ImagePatients:

15 603 patients ⩾45 years of age (median age 64 y, 70% men, 80% white) who had multiple atherothrombotic risk factors (type 1 or 2 diabetes, diabetic nephropathy, ankle brachial index <0.9, asymptomatic carotid stenosis ⩾70% of luminal diameter, ⩾1 carotid plaque, systolic blood pressure ⩾150 …

View Full Text


  • * See glossary.

  • Information provided by author.

  • For correspondence: Dr E J Topol, Case Western Reserve University, Cleveland, Ohio, USA. eric.topol{at}

  • Sources of funding: Sanofi-Aventis; Bristol-Myers Squibb; National Institutes of Health.

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd